Congress bans 'pay-for-delay' drug deals, forcing cheaper generics to market faster

What it does

This bill prohibits brand-name drug makers from paying generic or biosimilar manufacturers to delay market entry—a practice known as 'pay-for-delay.' It makes such agreements unlawful unless the payment is solely for unrelated goods/services, and allows the FTC to enforce the ban with civil penalties up to 3× the value of the improper payment. The bill also requires companies to file and certify all settlement agreements with the FTC and DOJ.

Why we flagged it

The bill's core mechanism is a prohibition on anti-competitive pay-for-delay settlements that artificially delay generic and biosimilar drug entry. It is a consumer-protection and competition measure, not a subsidy, carve-out, or commemorative act.

What the text implies

• The bill's 6-year statute of limitations (Section 6) may allow some historical pay-for-delay agreements to escape enforcement if filed before the lookback window closes, creating a brief window for settlement of old disputes.
• The 'clear and convincing evidence' standard in subsection (b) sets a high bar for companies to prove payments were for legitimate services, potentially shifting litigation risk toward brand-name manufacturers.
• The $7.5M cap on litigation expense reimbursement (subsection (c)(2)) may incentivize settlement of marginal patent claims, as companies cannot recover full legal costs through settlement.
• Forfeiture of 180-day exclusivity (Section 4) creates a new penalty for generic makers who violate the agreement prohibition, potentially deterring some generic entrants from challenging weak patents.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary consumers benefit from faster generic and biosimilar drug entry, which typically reduces prices and increases competition. The bill removes a mechanism that artificially delays cheaper alternatives, directly lowering drug costs for patients and the public.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• consumers (via lower drug prices)
• pharmacy benefit managers and insurers (via reduced drug costs)

Named in the bill

Federal Trade Commission (FTC), Department of Justice (DOJ), FDA (Food and Drug Administration), brand-name pharmaceutical manufacturers, generic drug manufacturers, biosimilar manufacturers, Medicare Prescription Drug, Improvement, and Modernization Act of 2003

Where it stands

• Oct 22, 2026 — Introduced · Congress.gov: “Introduced in House”
• Oct 22, 2026 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.